Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CLL 2020 | Prognostic value of high-sensitivity MRD assessment in CLL

Florence Cymbalista • 17 Nov 2020
ESH CLL 2020
Chronic Lymphocytic Leukemia Leukemia Antibodies Cyclophosphamide Fludarabine Rituximab

Florence Cymbalista, MD, PhD, Avicenne Hospital, Bobigny, France, discusses the prognostic value of high-sensitivity MRD assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia (CLL). Based on investigations from FILO group trial findings, high-sensitivity MRD in blood yielded additional prognostic information beyond the current standard sensitivity (0.01%). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florence Cymbalista

2:30
Towards strategies to optimize outcomes in CLL
Florence Cymbalista • 7 Oct 2022
2:07
Moving towards time-limited treatment in frontline CLL
Florence Cymbalista • 7 Oct 2022
2:27
The importance of TP53 & IGHV testing before treatment initiation in CLL
Florence Cymbalista • 7 Oct 2022
1:33
Challenges in interpreting the results of genomic tests in CLL
Florence Cymbalista • 7 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals